REVA Medical, Inc. Sample Contracts

REVA Medical, Inc. – EXECUTIVE EMPLOYMENT AGREEMENT (January 17th, 2019)

This Executive Employment Agreement (this “Agreement”) is made effective as of January 4, 2019 (the “Effective Date”), by and between REVA Medical, Inc. (the “Company”) and Leigh F. Elkolli (the “Executive”).

REVA Medical, Inc. – AMENDMENT #4 TO EXCLUSIVE LICENSE AGREEMENT #2 (August 3rd, 2018)

THIS AMENDMENT #4 TO EXCLUSIVE LICENSE AGREEMENT #2 (the “Amendment #4”) is entered into as of July 30, 2018 (“Amendment Effective Date”), by and between Reva Medical Inc. (“Licensee”) and Rutgers, The State University of New Jersey (“Rutgers”).

REVA Medical, Inc. – REVA Medical Provides Quarterly Cashflow Report for the Quarter Ended 30 June 2018 (July 31st, 2018)

As of 30 June 2018, the Company’s cash, cash equivalents and investment securities balance was US $10.9 million. This balance was broken out between cash of US $10.1 million and investment securities of US $735,000.  The 30 June 2018 cash balance of $10.1 million is a decrease of US $8.4 million from the 31 December 2017 balance of US $18.5 million, and a decrease of US $3.5 million from the 31 March 2018 balance.

REVA Medical, Inc. – RESTRICTED STOCK AGREEMENT (March 7th, 2018)

REVA Medical, Inc. (the “Company”) has granted to the Participant named in the Notice of Grant of Restricted Stock (the “Grant Notice”) to which this Restricted Stock Agreement (the “Agreement”) is attached an Award consisting of Shares subject to the terms and conditions set forth in the Grant Notice and this Agreement.  The Award has been granted pursuant to and shall in all respects be subject to the terms and conditions of the REVA Medical, Inc. 2010 Equity Incentive Plan (the “Plan”), as amended to the Date of Grant, the provisions of which are incorporated herein by reference.  By signing the Grant Notice, the Participant: (a) acknowledges receipt of and represents that the Participant has read and is familiar with the Grant Notice, this Agreement, the Plan and a prospectus for the Plan prepared in connection with the registration with the Securities and Exchange Commission of the Shares (the “Plan Prospectus”), (b) accepts the Award subject to all of the terms and conditions of

REVA Medical, Inc. – Consulting Agreement (March 7th, 2018)

This Consulting Agreement (“Agreement”) is made and entered into as of July 13, 2017 (“Effective Date”) by and between REVA Medical, Inc., a Delaware corporation, with its principal place of business located at 5751 Copley Dr., San Diego, CA 92111 (“Company”) and Robert K. Schultz (“Consultant”).

REVA Medical, Inc. – Consulting Agreement (March 7th, 2018)

This Consulting Agreement (the “Agreement”) is made and entered into as of the 5th day of July, 2017 (the “Effective Date”), by and between Reva Medical, Inc., a Delaware corporation, with its principal place of business located at 5751 Copley Drive, Suite B, San Diego, CA 92111 (“Company”) and the individual or entity designated in the signature block below as “Consultant.”

REVA Medical, Inc. – RESTRICTED STOCK UNITS AGREEMENT (March 7th, 2018)

Reva Medical, Inc. (the “Company”) has granted to the Participant named in the Notice of RSU Award (the “Award Notice”), to which this Restricted Stock Units Agreement (the “Agreement”) is attached, an Award consisting of Restricted Stock Units (“RSUs”) subject to the terms and conditions set forth in the Award Notice and this Agreement. The Award has been granted pursuant to and shall in all respects be subject to the terms conditions of the Reva Medical, Inc. 2010 Equity Incentive Plan (the “Plan”), as amended to the date of award, the provisions of which are incorporated herein by reference. By signing the Award Notice, the Participant (a) acknowledges receipt of and represents that the Participant has read and is familiar with the Award Notice, this Agreement, the Plan, and a prospectus for the Plan prepared in connection with the registration with the Securities and Exchange Commission of the shares issuable pursuant to the Award (the “Plan Prospectus”); (b) accepts the Award subj

REVA Medical, Inc. – Consulting Agreement (March 7th, 2018)

This Consulting Agreement (“Agreement”) is made and entered into as of September 11, 2017 (“Effective Date”) by and between REVA Medical, Inc., a Delaware corporation, with its principal place of business located at 5751 Copley Dr., San Diego, CA 92111 (“Company”) and Katrina L. Thompson (“Consultant”).

REVA Medical, Inc. – Preliminary Final Report on Appendix 4E Year Ended 31 December 2017 (March 5th, 2018)

This has been a transformative year for REVA. In the first half of 2017, REVA made the transition to a commercial enterprise with the launch of its Fantom bioresorbable scaffold (“BRS”) in Europe subsequent to receipt of CE Mark on April 3, 2017.  We shipped our first product to customers and commenced implants in July 2017.  Physicians that have used Fantom have been very positive about its performance and the features that differentiate it from first generation BRS, such as thinner strut profile, improved flexibility and full x-ray visibility.

REVA Medical, Inc. – SIXTH AMENDMENT TO TELECOM BUSINESS CENTER NNN LEASE (November 7th, 2017)

THIS SIXTH AMENDMENT TO TELECOM BUSINESS CENTER NNN LEASE ("Amendment"), dated for reference purposes only as of October 5, 2017, is entered into by and between GILDRED BUILDING COMPANY, a California corporation, doing business as Campus at Copley (“Landlord”), as successor in interest to HB COPLEY BUSINESS CENTER, LLC, a Delaware limited liability company (“Prior Landlord”) as successor in interest to ARI - Copley Business Center, LLC, ARI - CBC 1, LLC, ARI - CBC 2, LLC, ARI - CBC 3, LLC, ARI - CBC 4, LLC, ARI - CBC 5, LLC, ARI - CBC 6, LLC, ARI - CBC 7, LLC, ARI - CBC 8, LLC, ARI - CBC 9, LLC, ARI - CBC 10, LLC, ARI - CBC 11, LLC, ARI - CBC 12, LLC, ARI - CBC 13, LLC, ARI - CBC 14, LLC, ARI - CBC 15, LLC, ARI - CBC 16, LLC, ARI - CBC 17, LLC, ARI - CBC 18, LLC, ARI - CBC 19, LLC, ARI - CBC 20, LLC, ARI - CBC 21, LLC, ARI - CBC 22, LLC, ARI - CBC 23, LLC, ARI - CBC 24, LLC, ARI - CBC 25, LLC, ARI -CBC 26, LLC, ARI - CBC 27, LLC, ARI - CBC 28, LLC, ARI - CBC 29, LLC, ARI - CBC 30, LLC

REVA Medical, Inc. – EXECUTIVE EMPLOYMENT AGREEMENT (November 7th, 2017)

This Executive Employment Agreement (this “Agreement”) is made effective as of August 28, 2017 (the “Effective Date”), by and between REVA Medical, Inc. (the “Company”) and Brandi Roberts (the “Executive”).

REVA Medical, Inc. – Appendix 4C Quarter Ended 30 September 2017 (October 31st, 2017)

During the third quarter of 2017, the Company initiated commercial sales of the Fantom® bioresorbable scaffold (“BRS”). Product shipments included a combination of new customer orders and reorders from existing customers.

REVA Medical, Inc. – Appendix 4C Quarter Ended 30 June 2017 (July 31st, 2017)

During the second quarter of 2017, the Company achieved several significant milestones, in addition to its ongoing activities. The milestones include receipt of CE Mark on the Company’s Fantom scaffold, completion of a financing to provide funds for operating and capital needs, and commercialization activities that included hiring a Vice President of Sales and securing the first commercial customer. Fantom is a bioresorbable drug-eluting scaffold that utilizes the Company’s advanced proprietary polymer to allow thinner strut thickness and enhanced deliverability, while offering a unique property of being visible under x-ray.

REVA Medical, Inc. – Appendix 4C Quarter Ended 31 March 2017 (April 28th, 2017)

During the first quarter of 2017, the Company’s primary activities centered around preparing to commercialize its Fantom scaffold and securing ongoing financial resources for operating and capital needs. Fantom is a bioresorbable drug-eluting scaffold that utilizes the Company’s advanced proprietary polymer to allow thinner strut thickness and enhanced deliverability, while offering a unique property of being visible under x-ray.

REVA Medical, Inc. – SECOND AMENDMENT TO CONVERTIBLE NOTE DEED AND SUBORDINATION AGREEMENT (April 26th, 2017)

THIS SECOND AMENDMENT TO CONVERTIBLE NOTE DEED AND SUBORDINATION AGREEMENT (this “Amendment”), is made as of April 22, 2017, by and among Reva Medical, Inc. (the “Company”), GOLDMAN SACHS INTERNATIONAL and SENRIGAN MASTER FUND (each a “Noteholder”), and is entered into with respect to the Convertible Note Deed, dated  September 25, 2014, by and among the Company and the Noteholders, as amended by First Amendment to Convertible Note Deed dated February 11, 2016 (collectively, the “Agreement”).  Unless otherwise indicated, words and terms which are defined in the Agreement shall have the same meaning where used herein.

REVA Medical, Inc. – STOCK REPURCHASE AGREEMENT (April 26th, 2017)

This Stock Repurchase Agreement (this “Agreement”) is entered into as of April ___, 2017 (the “Effective Date”) by and between Reva Medical, Inc., a Delaware corporation (the “Company”), and Medtronic, Inc. (the “Stockholder”).

REVA Medical, Inc. – DATED 22 April 2017 (April 26th, 2017)
REVA Medical, Inc. – Appendix 4C Quarter Ended 31 December 2016 (January 30th, 2017)

The Company completed an application for CE Marking of its Fantom scaffold in August 2016 and successfully completed both on-site audits required for the approval process in October 2016, with no audit findings. Fantom is REVA’s bioresorbable drug-eluting scaffold that utilizes the Company’s advanced proprietary polymer to allow thinner strut thickness and enhanced deliverability, while offering its unique property of being visible under x-ray.

REVA Medical, Inc. – AMENDMENT #3 TO EXCLUSIVE LICENSE AGREEMENT # 2 (November 9th, 2016)

WHEREAS Reva Medical Inc. (“REVA”) and Rutgers, The State University of New Jersey (“Rutgers”), referred to collectively herein as “the Parties”, entered into an EXCLUSIVE LICENSE AGREEMENT NUMBER 2 (“License #2) effective July 1, 2010; and,

REVA Medical, Inc. – Appendix 4C Quarter Ended 30 September 2016 (October 28th, 2016)

The Company completed an application for CE Marking of its Fantom scaffold in August 2016, continues to collect data from its clinical trials, and is preparing for commercialization. Fantom is a bioresorbable drug-eluting scaffold that utilizes REVA’s advanced proprietary polymer to allow thinner strut thickness and enhanced deliverability, while offering its unique property of being visible under x-ray.

REVA Medical, Inc. – Appendix 4C Quarter Ended 30 June 2016 (July 29th, 2016)

The Company is continuing clinical testing, completing an application for CE Marking of its Fantom scaffold, and preparing for commercialization. Fantom is a bioresorbable drug-eluting scaffold that utilizes REVA’s advanced proprietary polymer to allow thinner strut thickness and enhanced deliverability, while offering its unique property of being visible under x-ray.

REVA Medical, Inc. – Appendix 4C Quarter Ended 31 March 2016 (April 29th, 2016)

During the first quarter of 2016, the Company’s operating activities continued to focus on the clinical study of its Fantom scaffold. In February 2016, the Company announced it had reached targeted enrollment of 110 patients in Cohort B of the FANTOM II clinical trial. Combined with the patients enrolled in Cohort A, which completed enrollment in October 2015 with 117 patients, a total of 240 patients are enrolled in the trial. Fantom is a bioresorbable drug-eluting scaffold that utilizes REVA’s advanced proprietary polymer to allow thinner strut thickness and enhanced deliverability, while offering its unique property of being visible under x-ray.

REVA Medical, Inc. – Preliminary Final Report on Appendix 4E Year Ended 31 December 2015 (February 26th, 2016)

Loss from operations of US$23,970,000, reflecting the Company’s progress with its Fantom® bioresorbable scaffold. Following the successful first human implants of Fantom in December 2014, the Company launched its CE clinical trial in March 2015, with overall enrollment targeted at 220 patients. On 30 September 2015, the Company announced enrollment of 110 patients in the first cohort of the trial and on 24 February 2016, the Company announced it had completed the second cohort of 110 patient enrollments. The data from the first cohort of patients is intended to be used in a CE Mark application in the third quarter of 2016 and the data from the second cohort will be used for market support and other commercial purposes.

REVA Medical, Inc. – FIRST AMENDMENT TO CONVERTIBLE NOTE DEED (February 17th, 2016)

THIS FIRST AMENDMENT TO CONVERTIBLE NOTE DEED (this “Amendment”), is made as of February 11, 2016, by and among REVA Medical, Inc. (the “Company”), and Goldman Sachs International and Senrigan Master Fund (the “Noteholders”), and is entered into with respect to the Convertible Note Deed, dated  September 25, 2014, by and among the Company and the Noteholders (collectively, the “Deed”).  Unless otherwise indicated, words and terms which are defined in the Deed shall have the same meaning where used herein.

REVA Medical, Inc. – Appendix 4C Quarter Ended 31 December 2015 (January 28th, 2016)

During the fourth quarter of 2015, the Company’s operating activities continued to focus on the clinical study of its Fantom scaffold. In addition to announcing the enrollment of 110 patients on 30 September 2015, the Company also presented preliminary clinical data on Fantom at the Transcatheter Cardiovascular Therapeutics (“TCT”) conference in October, which was being held in San Francisco. Fantom is a bioresorbable drug-eluting scaffold that utilizes REVA’s advanced proprietary polymer to allow thinner strut thickness and enhanced deliverability, while offering its unique property of being visible under x-ray.

REVA Medical, Inc. – EXCLUSIVE LICENSE AGREEMENT NUMBER Between REVA Medical, Inc. and RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (November 9th, 2015)

THIS Exclusive License Agreement Number 2 (the "Agreement") is made and is effective as of the 1st day of July 2010, (the “Effective Date”) by and between Rutgers, The State University Of New Jersey, having its statewide Office of Technology Commercialization at ASB Annex III, 3 Rutgers Plaza, New Brunswick, New Jersey 08901-8559, (hereinafter referred to as "Rutgers"), and REVA Medical, Inc., a California corporation having a principal place of business at 5751 Copley Drive, Suite B, San Diego, CA 92111 (hereinafter referred to as "Licensee").

REVA Medical, Inc. – Appendix 4C Quarter Ended 30 September 2015 (October 30th, 2015)

Effective 23 September 2015, the Company welcomed its incoming Chief Executive Officer, Regina Groves. With an extensive background in coronary medical devices and executive management, most recently at Medtronic, Inc., she is positioning the Company for commercialization of its Fantom® scaffold, a next generation drug-eluting bioresorbable coronary scaffold. Robert Stockman, REVA’s former CEO, remains non-executive Chairman of the Board.

REVA Medical, Inc. – EXECUTIVE EMPLOYMENT AGREEMENT (August 21st, 2015)

This Executive Employment Agreement (this “Agreement”) is made effective as of September 21, 2015 (the “Effective Date”), by and between REVA Medical, Inc. (the “Company”) and Regina Groves (the “Executive”).

REVA Medical, Inc. – Appendix 4C Quarter Ended 30 June 2015 (July 31st, 2015)

San Diego, California and Sydney, Australia (Friday, 31 July 2015, AEST) — REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) is pleased to provide the attached Appendix 4C Quarterly Report for the quarter ended 30 June 2015. The Appendix 4C is unaudited.

REVA Medical, Inc. – Appendix 4C Quarter Ended 31 March 2015 (April 30th, 2015)

San Diego, California and Sydney, Australia (Thursday, 30 April 2015, AEST) — REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) is pleased to provide the attached Appendix 4C Quarterly Report for the quarter ended 31 March 2015. The Appendix 4C is unaudited.

REVA Medical, Inc. – Preliminary Final Report Appendix 4E Year Ended 31 December 2014 HEAD OFFICE: 5751 Copley Drive, San Diego, CA 92111 · +1 (858) 966-3000 · +1 (858) 966-3099 (FAX)· www.revamedical.com AUSTRALIAN OFFICE: Suite 4, Level 14, 6 O’Connell Street, Sydney NSW 2000 · +61 2 9237 2800 ARBN 146 505 777 · REVA Medical, Inc., is a foreign company incorporated in Delaware, USA, whose stockholders have limited liability (February 27th, 2015)
REVA Medical, Inc. – Appendix 4C Quarter Ended 31 December 2014 (January 30th, 2015)

San Diego, California and Sydney, Australia (Friday, 30 January 2015, AEDT) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) is pleased to provide the attached Appendix 4C Quarterly Report for the quarter ended 31 December 2014. The Appendix 4C is unaudited.

REVA Medical, Inc. – January 15, 2015 J.P. Morgan 2015 Healthcare Conference Important Notice Information is a Synopsis Only This presentation only contains a synopsis of information on the Company and, accordingly, no reliance may be placed for any purpose whatsoever on the sufficiency or completeness of such information. Information presented in this presentation is subject to change without notice and REVA does not have any responsibility or obligation to inform you of any matter arising or coming to their notice after the date of this presentation, which may affect any matter in the presentation. Currency Refe (January 15th, 2015)
REVA Medical, Inc. – Issuance of Convertible Notes and Options (November 17th, 2014)

San Diego, California and Sydney, Australia (Friday, 14 November 2014 AEDT) — REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) announces that 250 convertible notes with a face value of US$100,000 each and 8,750,000 options to purchase 8,750,000 shares of common stock have been issued. These issuances were made under the Prospectus lodged with the Australian Securities Exchange and the Australian Securities and Investments Commission on 24 October 2014 and in accordance with the Convertible Note Deed dated 25 September 2014. Details of the issuances are provided in the attached Appendix 3B. Also reflected in the Appendix 3B are the cancellation during October 2014 of 93,125 employee options under the Company’s Equity Incentive Plans.

REVA Medical, Inc. – AMENDMENT #2 to Exclusive License Agreement Number 2 (November 6th, 2014)

Whereas Reva Medical, Inc.(“REVA”) and Rutgers, The State University Of New Jersey (“Rutgers”), referred to collectively herein as “the Parties”, entered into an EXCLUSIVE LICENSE AGREEMENT NUMBER 2 (“License No. 2”) effective July 1, 2010;